Compare OZ & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OZ | PROF |
|---|---|---|
| Founded | 2020 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.7M | 270.7M |
| IPO Year | 2020 | 2017 |
| Metric | OZ | PROF |
|---|---|---|
| Price | $52.13 | $6.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 18.3K | ★ 356.4K |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | N/A | ★ 1.41 |
| Revenue | $9,187,000.00 | ★ $16,098,000.00 |
| Revenue This Year | N/A | $115.41 |
| Revenue Next Year | N/A | $60.63 |
| P/E Ratio | ★ N/A | $4.60 |
| Revenue Growth | ★ 243.44 | 50.73 |
| 52 Week Low | $48.50 | $3.90 |
| 52 Week High | $69.00 | $8.95 |
| Indicator | OZ | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 49.70 | 53.97 |
| Support Level | $52.02 | $5.21 |
| Resistance Level | $65.22 | $7.08 |
| Average True Range (ATR) | 1.86 | 0.49 |
| MACD | -0.15 | 0.14 |
| Stochastic Oscillator | 20.50 | 83.33 |
Belpointe PREP LLC is a qualified opportunity fund. The company's investments consist of properties located in qualified opportunity zones for the development or redevelopment of multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, mixed-use, data centers, and solar projects located throughout the United States and its territories. Company currently has two reporting segments, commercial: includes properties such as office, retail centers, and warehouses; and mixed-use: includes properties that blend both residential and retail components within a single real estate asset.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.